Could a diabetes drug duo protect transplanted kidneys?

NCT ID NCT05938712

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing whether a 12-week combination of two common diabetes drugs—dapagliflozin (Farxiga) and semaglutide (Ozempic)—is safe and helpful for people who have received a kidney transplant. The 20 participants will take both drugs and be monitored for changes in kidney function and other health markers. The goal is to see if this combo can improve outcomes for transplant recipients, with or without type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (Farxiga) and semaglutide (Ozempic)
What this could lead to: If it works, this could point toward a new way to protect kidney function and manage weight or blood sugar in kidney transplant recipients.
What could go wrong: This is a very small, early pilot study with only 20 people, so results may not apply to everyone. The drugs also carry risks like dehydration or gastrointestinal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT RECIPIENTS

Contacts and locations

Locations

Toronto General Hospital
RECRUITING

Toronto, Ontario, M5G 2N2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.